How long should you take weight loss injections for?

You've been taking the injections for a while, and now you're wondering if there's a finish line

That's one of the most common questions our prescribers hear. You started the medicine, it's working, and somewhere along the way a nagging thought appears: how long is this supposed to go on for? It's a reasonable thing to wonder, and the honest answer is that for most people these medicines are designed for sustained use rather than a defined endpoint.

Unlike a course of antibiotics, GLP-1 and dual-agonist medicines work while you're taking them. Appetite regulation, the rate at which your stomach empties, and the signals that govern how your body handles calories, all of these are influenced by the medicine. When the medicine stops, those effects stop with it. The NHS's own patient information on weight loss injections is straightforward on this point: weight regain after stopping is a recognised pattern, not an unusual event. Framing it as a personal failing misses the biology entirely.

This doesn't mean you take these medicines forever regardless of outcome. It means the decision to continue, reduce or stop is a clinical one, made with evidence, not habit.

What UK guidance actually specifies about duration

The two licensed injectable weight loss medicines in the UK, semaglutide (Wegovy) and tirzepatide (Mounjaro), sit in different positions when it comes to official duration guidance.

For semaglutide, NICE's technology appraisal TA875 recommends its use only within a specialist weight management service and for a maximum of two years. That limit applies to its NHS recommendation specifically. Outside the NHS, the licence itself does not impose a two-year cap, but a private prescriber should still be asking the same clinical questions a NICE committee would: is treatment still working, is it still safe, are the benefits still proportionate?

For tirzepatide, NICE's recommendation (TA1026, published December 2024) does not set a fixed time limit in the same way. It does specify that if a patient has not lost at least 5% of their body weight after six months on the highest tolerated dose, continuing should be reviewed. That's a trigger for a conversation, not an automatic end, but it is a clear signal that continuing without meaningful benefit isn't appropriate.

If you're trying to understand how long staying on weight loss injections is realistic for most people, the truthful picture involves individual response, comorbidities and what stopping has historically looked like for that person.

The clinical logic behind long-term prescribing

Weight management medicines are more like blood pressure treatments than like a diet plan with an end date. Hypertension doesn't resolve because you took a pill for six months; obesity, as a condition, doesn't either. NHS guidance on obesity treatment recognises this, sustained support tends to produce better long-term outcomes than short interventions followed by nothing.

That said, long-term prescribing isn't open-ended. At nume, a prescriber personally reviews every repeat order before anything is dispensed. There's no automatic renewal where the medicine just keeps arriving. Each review is a genuine clinical checkpoint: has weight loss continued or stabilised at a meaningful level? Are side effects manageable? Has anything changed in the patient's health that affects the risk-benefit balance? These are the questions that govern whether treatment continues.

For people considering the practical side of ongoing treatment, details like managing injections while travelling become relevant over time, the kind of question that only matters once you're settled into longer-term use. For context on what one transparent price includes at each stage, the cost context page sets out what to expect from private treatment.

When stopping might be the right decision

Stopping is sometimes the right clinical call. If the medicine hasn't produced meaningful weight loss at the highest tolerated dose after six months, continuing is unlikely to change that. If side effects are persistent and severe, the prescriber may decide the balance has shifted. If a patient becomes pregnant, is breastfeeding, or is actively trying to conceive, weight loss injections are not recommended, the prescriber should be told immediately so treatment can be managed appropriately.

Stopping should ideally be planned with the prescriber rather than done abruptly. There's no serious physical risk in stopping a GLP-1 or tirzepatide suddenly, but returning hunger signals can be sharp, and having a plan (whether that's a tapering schedule or a lifestyle support structure) tends to produce better outcomes than an unplanned stop.

If you're still deciding whether these medicines are right for you at all, this page on whether weight loss injections are suitable covers the broader eligibility and suitability picture, and this one sets out who shouldn't use them. The free consultation at nume is where a GPhC-registered prescriber reviews your individual situation and guides the decision, including, eventually, the question of when and how to stop.